Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Wyeth | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Wyeth

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Wyeth

2Q Revenues: $5.2 billion (+9%)

2Q Earnings: $1 billion (+9%)

YTD Revenues: $10 billion (+8%)

YTD Earnings: $2.2 billion (+6%)

Comments: Pharmaceuticals revenue growth of 11% for quarter was driven by Enbrel and Prevnar. Enbrel sales (outside the U.S. and Canada) were $370 million, up 36% and Prevnar sales were $518 million, an increase of 60%. The company submitted two NDAs in the quarter, for bazedoxifene (osteoporosis) and desvenlafaxine succinate (vasomotor symptoms). Also, Tygacil was approved in Europe.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters